Gene therapy company Krystal Biotech (KRYS) intends to raise up to $35 million in gross proceeds from an IPO of its common stock.

Krystal Biotech is a pre-clinical stage company focused on gene therapy that provides clinical benefit for patients who suffer from rare, debilitating disorders.

Given the long road ahead for Krystal and the extremely cautious regulatory environment for gene-based therapies, I’m skeptical of the value of investing in such an untested company.

I’ll provide a final opinion when we know more details about the IPO.

READ FULL ARTICLE HERE